Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 2.04
OREX's Cash to Debt is ranked lower than
52% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.34 vs. OREX: 2.04 )
Ranked among companies with meaningful Cash to Debt only.
OREX' s 10-Year Cash to Debt Range
Min: 1.43  Med: 55.00 Max: No Debt
Current: 2.04
Equity to Asset -0.02
OREX's Equity to Asset is ranked lower than
98% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. OREX: -0.02 )
Ranked among companies with meaningful Equity to Asset only.
OREX' s 10-Year Equity to Asset Range
Min: -3.15  Med: 0.44 Max: 0.86
Current: -0.02
-3.15
0.86
F-Score: 5
Z-Score: -2.22
M-Score: 11.57
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -32.78
OREX's Operating margin (%) is ranked lower than
86% of the 667 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.78 vs. OREX: -32.78 )
Ranked among companies with meaningful Operating margin (%) only.
OREX' s 10-Year Operating margin (%) Range
Min: -107754.55  Med: -4536.58 Max: -54.99
Current: -32.78
-107754.55
-54.99
Net-margin (%) -43.97
OREX's Net-margin (%) is ranked lower than
88% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.89 vs. OREX: -43.97 )
Ranked among companies with meaningful Net-margin (%) only.
OREX' s 10-Year Net-margin (%) Range
Min: -105954.55  Med: -4415.71 Max: -67.59
Current: -43.97
-105954.55
-67.59
ROE (%) -291.39
OREX's ROE (%) is ranked lower than
98% of the 696 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. OREX: -291.39 )
Ranked among companies with meaningful ROE (%) only.
OREX' s 10-Year ROE (%) Range
Min: -235.61  Med: -109.88 Max: -42.04
Current: -291.39
-235.61
-42.04
ROA (%) -15.52
OREX's ROA (%) is ranked lower than
81% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.32 vs. OREX: -15.52 )
Ranked among companies with meaningful ROA (%) only.
OREX' s 10-Year ROA (%) Range
Min: -879.2  Med: -70.53 Max: -19.09
Current: -15.52
-879.2
-19.09
ROC (Joel Greenblatt) (%) -619.75
OREX's ROC (Joel Greenblatt) (%) is ranked lower than
89% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.13 vs. OREX: -619.75 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OREX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -193375  Med: -8377.69 Max: -3874.08
Current: -619.75
-193375
-3874.08
Revenue Growth (3Y)(%) 73.50
OREX's Revenue Growth (3Y)(%) is ranked higher than
98% of the 546 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. OREX: 73.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OREX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 0.00 Max: 73.5
Current: 73.5
0
73.5
EBITDA Growth (3Y)(%) -23.00
OREX's EBITDA Growth (3Y)(%) is ranked lower than
83% of the 492 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. OREX: -23.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OREX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -24.30 Max: -8
Current: -23
EPS Growth (3Y)(%) -18.00
OREX's EPS Growth (3Y)(%) is ranked lower than
76% of the 453 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. OREX: -18.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OREX' s 10-Year EPS Growth (3Y)(%) Range
Min: -55.4  Med: -18.00 Max: 153.4
Current: -18
-55.4
153.4
» OREX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

OREX Guru Trades in Q3 2014

RS Investment Management 2,229,642 sh (+2.32%)
» More
Q4 2014

OREX Guru Trades in Q4 2014

RS Investment Management Sold Out
» More
Q1 2015

OREX Guru Trades in Q1 2015

John Burbank 51,980 sh (New)
Paul Tudor Jones 37,027 sh (New)
Steven Cohen 2,048,300 sh (New)
» More
Q2 2015

OREX Guru Trades in Q2 2015

Jim Simons 420,400 sh (New)
Steven Cohen Sold Out
John Burbank Sold Out
Paul Tudor Jones 14,200 sh (-61.65%)
» More
» Details

Insider Trades

Latest Guru Trades with OREX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 5.64
OREX's P/S is ranked lower than
71% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.13 vs. OREX: 5.64 )
Ranked among companies with meaningful P/S only.
OREX' s 10-Year P/S Range
Min: 5.22  Med: 161.38 Max: 1495
Current: 5.64
5.22
1495
PFCF 6.89
OREX's PFCF is ranked higher than
94% of the 267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 42.27 vs. OREX: 6.89 )
Ranked among companies with meaningful PFCF only.
OREX' s 10-Year PFCF Range
Min: 6.4  Med: 28.84 Max: 35.22
Current: 6.89
6.4
35.22
POCF 9.62
OREX's POCF is ranked higher than
86% of the 387 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.20 vs. OREX: 9.62 )
Ranked among companies with meaningful POCF only.
OREX' s 10-Year POCF Range
Min: 5.91  Med: 25.17 Max: 79.5
Current: 9.62
5.91
79.5
Current Ratio 5.17
OREX's Current Ratio is ranked higher than
79% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. OREX: 5.17 )
Ranked among companies with meaningful Current Ratio only.
OREX' s 10-Year Current Ratio Range
Min: 1.99  Med: 6.19 Max: 19.3
Current: 5.17
1.99
19.3
Quick Ratio 5.04
OREX's Quick Ratio is ranked higher than
81% of the 617 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. OREX: 5.04 )
Ranked among companies with meaningful Quick Ratio only.
OREX' s 10-Year Quick Ratio Range
Min: 1.99  Med: 6.19 Max: 19.3
Current: 5.04
1.99
19.3
Days Sales Outstanding 39.20
OREX's Days Sales Outstanding is ranked higher than
79% of the 598 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 71.39 vs. OREX: 39.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
OREX' s 10-Year Days Sales Outstanding Range
Min: 8.2  Med: 12.55 Max: 16.9
Current: 39.2
8.2
16.9

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.04
OREX's Price/Median PS Value is ranked higher than
99% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.28 vs. OREX: 0.04 )
Ranked among companies with meaningful Price/Median PS Value only.
OREX' s 10-Year Price/Median PS Value Range
Min: 0.06  Med: 0.81 Max: 8.8
Current: 0.04
0.06
8.8
Earnings Yield (Greenblatt) (%) -7.54
OREX's Earnings Yield (Greenblatt) (%) is ranked lower than
83% of the 695 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. OREX: -7.54 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OREX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -8.35  Med: 155.00 Max: 3901
Current: -7.54
-8.35
3901

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 129 80 201
EPS($) 0.14 -0.11 0.59
EPS without NRI($) 0.14 -0.11 0.59

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:JXS.Germany,
Orexigen Therapeutics Inc was incorporated in Delaware in September 2002. Company is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates are NB32, which has completed Phase III clinical trials and which is currently being studied in a cardiovascular outcomes trial, and Empatic, which has completed Phase II clinical trials. Both NB32 and Empatic regulate appetite and energy expenditure through central nervous system activity. NB32 is a fixed dose combination of bupropion and naltrexone. Company develops its product candidates for large markets traditionally served by primary care physicians. In order to effectively promote NB32 to these physicians, in September 2010, it entered into a collaboration agreement with Takeda to develop and commercialize NB32 in the United States, Canada and Mexico. It maintains an aggressive intellectual property strategy, which includes patent and trademark filings in multiple jurisdictions including the United States and other commercially significant markets. It relies on a combination of in-licensed patent rights, its own patent rights, trademarks, trade secrets and know-how to protect NB32 and Empatic. Its products used in clinical trials have been produced by outside contractors under its supervision. Company competes with AstraZeneca, Athersys, Inc., Bristol-Myers Squibb, Norgine BV, Novo Nordisk A/S, among others.
» More Articles for OREX

Headlines

Articles On GuruFocus.com
Oxford Industries (OXM) Solid Growth Metrics, Orexigen Therapeutics (OREX) European Anti-Obesity App Mar 27 2015 
Orexigen Therapeutics' Bright Future Mar 03 2015 
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
Weekly CEO Sells Highlight: Orexigen Therapeutics Inc, Gas Natural Inc, The Middleby Corporation, an Jul 15 2012 
Weekly CEO Sells Highlight: Gas Natural Inc, Encore Bancshares Inc, Staples Inc, and Orexigen Therap Jul 08 2012 
Arena Facing Increased Pressure from Peers Apr 23 2012 
Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 
Vivus Could Rocket on Success of Qnexa Apr 13 2012 
Steve Cohen Bets On Orexigen Ahead of FDA Approval Jan 31 2011 
Orexigen Therapeutics Inc. Reports Operating Results (10-Q) Nov 04 2010 

More From Other Websites
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Aug 21 2015
How the bulls are playing Orexigen Aug 21 2015
OREXIGEN THERAPEUTICS, INC. Financials Aug 18 2015
10-Q for Orexigen Therapeutics, Inc. Aug 09 2015
OREXIGEN THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report Aug 07 2015
Orexigen 2Q Loss Wider Than Expected, Settles with Takeda - Analyst Blog Aug 07 2015
Edited Transcript of OREX earnings conference call or presentation 6-Aug-15 12:00pm GMT Aug 06 2015
Orexigen Therapeutics Inc Earnings Call scheduled for 8:00 am ET today Aug 06 2015
Orexigen reports 2Q loss Aug 06 2015
Orexigen reports 2Q loss Aug 06 2015
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results... Aug 06 2015
Q2 2015 Orexigen Therapeutics Inc Earnings Release - Before Market Open Aug 06 2015
Orexigen Therapeutics Reports Financial and Business Results for the Second Quarter Ended June 30,... Aug 06 2015
Orexigen Announces Korean Distributorship Agreement with Kwang Dong Pharmaceutical Company Aug 06 2015
Orexigen and Takeda Announce an Amended and Restated Collaboration Agreement Aug 06 2015
Orexigen Therapeutics to Provide Business Update and Discuss Second Quarter 2015 Financial Results... Jul 24 2015
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jun 26 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK